These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
604 related articles for article (PubMed ID: 33049623)
1. Liquid biopsy in lymphoma: Molecular methods and clinical applications. Cirillo M; Craig AFM; Borchmann S; Kurtz DM Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623 [TBL] [Abstract][Full Text] [Related]
2. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Shields MD; Chen K; Dutcher G; Patel I; Pellini B Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272 [TBL] [Abstract][Full Text] [Related]
3. Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas. Meriranta L; Pitkänen E; Leppä S Semin Hematol; 2023 Jul; 60(3):132-141. PubMed ID: 37455222 [TBL] [Abstract][Full Text] [Related]
4. Detection of Circulating Tumor DNA in Lymphoma Patients. Bruscaggin A; Pini K; Rossi D Methods Mol Biol; 2025; 2865():475-490. PubMed ID: 39424738 [TBL] [Abstract][Full Text] [Related]
5. cfDNA-Based NGS IG Analysis in Lymphoma. Pott C; Kotrova M; Darzentas N; Brüggemann M; Khouja M; Methods Mol Biol; 2022; 2453():101-117. PubMed ID: 35622323 [TBL] [Abstract][Full Text] [Related]
6. Methods for Measuring ctDNA in Lymphomas. Rossi D; Condoluci A; Spina V; Gaidano G Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211 [TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy and its role in an advanced clinical trial for lung cancer. Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770 [TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy: current technology and clinical applications. Nikanjam M; Kato S; Kurzrock R J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847 [TBL] [Abstract][Full Text] [Related]
9. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. García-Pardo M; Makarem M; Li JJN; Kelly D; Leighl NB Br J Cancer; 2022 Sep; 127(4):592-602. PubMed ID: 35347327 [TBL] [Abstract][Full Text] [Related]
10. Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries. Alcaide M; Rushton C; Morin RD Methods Mol Biol; 2019; 1956():383-435. PubMed ID: 30779047 [TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. Arisi MF; Dotan E; Fernandez SV Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259 [TBL] [Abstract][Full Text] [Related]
12. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review. Vymetalkova V; Cervena K; Bartu L; Vodicka P Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199 [TBL] [Abstract][Full Text] [Related]
13. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing. Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539 [TBL] [Abstract][Full Text] [Related]
14. Clinical applications of circulating tumor DNA in central nervous system lymphoma. Foerster AK; Lauer EM; Scherer F Semin Hematol; 2023 Jul; 60(3):150-156. PubMed ID: 37442670 [TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175 [TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside? Cherng HJ; Herrera A Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685 [TBL] [Abstract][Full Text] [Related]
17. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review. Krebs MG; Malapelle U; André F; Paz-Ares L; Schuler M; Thomas DM; Vainer G; Yoshino T; Rolfo C JAMA Oncol; 2022 Dec; 8(12):1830-1839. PubMed ID: 36264554 [TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy in breast cancer: A comprehensive review. Alimirzaie S; Bagherzadeh M; Akbari MR Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931 [TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma. Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723 [TBL] [Abstract][Full Text] [Related]
20. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review). Chen H; Zhou Q Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]